[Bopindolol does not affect normal glucose and lipid metabolism in hypertensive patients].
The authors administered to ten patients with mild to medium severe hypertension and with a normal glucose tolerance and serum lipid spectrum bopindolol in amounts of 0.5 to 2 mg/day in the course of 12 months. They revealed: a) bopindolol reduced effectively the blood pressure with a maximum decline already during the first month, b) It reduced significantly the heart rate, c) it did not cause deterioration of the glucose tolerance and did not interfere with the response of immunoreactive insulin (IRI) after a glucose load, d) it did not influence significantly the levels of lipoprotein cholesterol, total cholesterol, VLDL cholesterol, HDL cholesterol; within the reference range a slight increase of LDL cholesterol was recorded during the 12th month; e) it did not influence the concentration of triglycerides, apolipoprotein A1 and apolipoprotein B.
Fedelesová
V
V
Spustová
V
V
Hucková
M
M
Kovác
G
G
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008055:Lipids / Q000097:blood*; D008297:Male; D010869:Pindolol / Q000031:analogs & derivatives
D000319:Adrenergic beta-Antagonists; D001786:Blood Glucose; D008055:Lipids; D010869:Pindolol; C036007:bopindolol
Bopindolol neovplyvnuje normálny metabolizmus glukózy a lipidov u hypertonikov.